Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 18Terminated 10Active not recruiting 3Withdrawn 2Recruiting 1No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 2EGFR-mutant Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × capmatinib × Clear all
NCT05488314 2026-06-05

METalmark

Janssen Research & Development, LLC

Phase 1/2 Active not recruiting
57 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Novartis

Phase 2 Active not recruiting
29 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡